Patients with BRCA1 mutations in breast cancer benefit more from platinum-based protocols than patients with BRCA2 mutations, suggesting that patients with BRCA1 mutations may be more sensitive to platinum-based drug therapy (24). Here, BRCA2 is linked to breast carcinoma.